Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

"The SGR is a transformative project for Kisumu and the entire western Kenya region. This extension will bring much-needed ...

Eradivir is a Purdue Strategic Ventures portfolio company. Eradivir’s goal is to focus the power of the immune system to treat disease. The company is developing the BAiT platform (Bispecific ...

Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.

Beckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...

Topline results from the core stage of the Phase 2b clinical trial are expected in mid-2025. “We are impressed by the Beckley Psytech team’s execution of the Phase 2b clinical trial of BPL-003 ...

Alto Neuroscience, Inc.’s ANRO share price has dipped by 10.13%, which has investors questioning if this is right time to buy ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...